|Mr. Jackie Peter Burnett||Pres, CEO & Chairman||466.56k||N/A||N/A|
|Mr. Guillermo Martin Delmonte||COO, Interim CFO & Corp. Sec.||325.19k||N/A||N/A|
RAMM Pharma Corp. engages in the research and development, production, and sale of cannabinoid pharmaceutical formulations, pharmaceuticals, cosmetics, nutraceutical products, and resale of medical supplies products. The company offers Epifractán, a cannabinoid pharmaceutical drug for the treatment of various medical conditions and pathologies; XALEX 10, a prescription pharmaceutical formulation for the treatment of refractory epilepsy; and NettaLife, a cannabis-based product for pets. It also offers cosmetic products, such as cannabipiel nite, cannabipiel body lotion, cannabipiel hair conditioners, cannabipiel liquid soaps, cannabipiel tite, cannabipiel cleaning emulsions, cannabipiel shampoos, cannabipiel lite, and cannbipiel facial tonics. In addition, the company also engages in the agricultural business. The company was formerly known as MTC Growth Fund-I Inc. and changed its name to RAMM Pharma Corp. in October 2019. The company was incorporated in 1987 and is based in Toronto, Canada.
RAMM Pharma Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.